Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies

Background: This study was performed to evaluate the pharmacokinetics, bioequivalence, and feasibility of a combined oral formulation of 5-flurouracil (5-FU) and eniluracil (Glaxo Wellcome Inc., Research Triangle Park, North Carolina), an inactivator of dihydropyrimidine dehydrogenase (DPD). The rat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2000-10, Vol.11 (10), p.1313-1322
Hauptverfasser:	Ochoa, L., Hurwitz, H. I., Wilding, G., Cohen, D., Thomas, J. P., Schwartz, G., Monroe, P., Petros, W. P., Ertel, V. Ph, Hsieh, A., Hoffman, C., Drengler, R., Magnum, S., Rowinsky, E. K.
Format:	Artikel
Sprache:	eng
Schlagworte:	5-fluorouracil 776C85 Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use bioequivalence Biological and medical sciences Chemotherapy Cross-Over Studies dihydropyrimidine dehydrogenase inhibitor Dihydrouracil Dehydrogenase (NADP) eniluracil Enzyme Inhibitors - administration & dosage Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - pharmacokinetics Humans Male Medical sciences Middle Aged Neoplasms - drug therapy Oxidoreductases - antagonists & inhibitors pharmacokinetics Pharmacology. Drug treatments Therapeutic Equivalency Uracil - administration & dosage Uracil - adverse effects Uracil - analogs & derivatives Uracil - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!